FoxM1 insufficiency hyperactivates Ect2-RhoA-mDia1 signaling to drive cancer
- 11 October 2020
- journal article
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableFunding Information
- Mayo Clinic Graduate School of Biomedical Sciences
- U.S. Department of Health & Human Services | National Institutes of Health (T32 GM65841)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA096985, R01 CA126828, R01 CA168709)
This publication has 66 references indexed in Scilit:
- Comprehensive Molecular Characterization of the Hippo Signaling Pathway in CancerCell Reports, 2018
- A RhoA-FRET Biosensor Mouse for Intravital Imaging in Normal Tissue Homeostasis and Disease ContextsCell Reports, 2017
- Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53 -Driven Lung AdenocarcinomaCancer Cell, 2017
- Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer EvolutionCancer Cell, 2015
- Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling CircuitryCancer Cell, 2014
- Targeting FOXM1 in cancerBiochemical Pharmacology, 2013
- Comparative Genomics of Esophageal Adenocarcinoma and Squamous Cell CarcinomaThe Annals of Thoracic Surgery, 2012
- The guanine nucleotide exchange factor (GEF) Ect2 is an oncogene in human cancerAdvances in Enzyme Regulation, 2009
- A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content ScreenCell, 2006
- Rho GTPase expression in tumourigenesis: Evidence for a significant linkBioEssays, 2005